Oncolytics Biotech Inc. Collaborators Present Positive Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Results at iSBTc Annu... ( http://www.o This press release conta...)

HOME >> BIOLOGY >> TECHNOLOGY

Oncolytics Biotech Inc. Collaborators Present Positive Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Results at iSBTc Annual Meeting

Date:11/3/2008

http://www.oncolyticsbiotech.com.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the implication of the materials presented at this meeting with respect to REOLYSIN(R), the Company's expectations related to the results of trials investigating delivery of REOLYSIN(R), the Company's analysis of the results of the Phase I/II trials and the Company's belief as to the potential of REOLYSIN(R) as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN(R) as a cancer treatment, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN(R), uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Post Your Comments:

Oncolytics Biotech Inc. Collaborators Present Positive Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Results at iSBTc Annu...( http://www.o This press release conta...)